These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 30719729)
1. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients. Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729 [TBL] [Abstract][Full Text] [Related]
2. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801 [TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. Ikeda T; Kanazawa N; Furukawa F J Dermatol; 2012 Jun; 39(6):531-5. PubMed ID: 22168306 [TBL] [Abstract][Full Text] [Related]
5. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI. Bein D; Kuehn E; Meuth AM; Amler S; Haust M; Nyberg F; Sauerland C; Luger TA; Bonsmann G; Kuhn A J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):652-9. PubMed ID: 20849444 [TBL] [Abstract][Full Text] [Related]
7. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus. Momose Y; Arai S; Eto H; Kishimoto M; Okada M J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Biazar C; Sigges J; Patsinakidis N; Ruland V; Amler S; Bonsmann G; Kuhn A; Autoimmun Rev; 2013 Jan; 12(3):444-54. PubMed ID: 23000206 [TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. Morita S; Takahashi T; Yoshida Y; Yokota N Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870 [TBL] [Abstract][Full Text] [Related]
10. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872 [TBL] [Abstract][Full Text] [Related]
11. Cutaneous lupus erythematosus: diagnosis and treatment. Okon LG; Werth VP Best Pract Res Clin Rheumatol; 2013 Jun; 27(3):391-404. PubMed ID: 24238695 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. Avgerinou G; Papafragkaki DK; Nasiopoulou A; Arapaki A; Katsambas A; Stavropoulos PG J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):762-7. PubMed ID: 21707772 [TBL] [Abstract][Full Text] [Related]
14. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674 [TBL] [Abstract][Full Text] [Related]
15. [Current diagnosis of cutaneous lupus erythematosus]. Haust M; Bonsmann G; Kuhn A Dtsch Med Wochenschr; 2006 Jul; 131(28-29):1594-8. PubMed ID: 16823708 [TBL] [Abstract][Full Text] [Related]
16. Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. Oh EH; Kim EJ; Ro YS; Ko JY J Dermatol; 2018 Apr; 45(4):436-443. PubMed ID: 29423919 [TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine does not impair antibody response to 13-valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus-A pilot study. Pelka K; Matyja-Bednarczyk A; Wojas-Pelc A; Pastuszczak M Dermatol Ther; 2021 Jul; 34(4):e15013. PubMed ID: 34056799 [TBL] [Abstract][Full Text] [Related]
18. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Shi H; Gudjonsson JE; Kahlenberg JM Curr Opin Rheumatol; 2020 May; 32(3):208-214. PubMed ID: 32141953 [TBL] [Abstract][Full Text] [Related]
19. Dermatologic Manifestations, Histologic Features and Disease Progression among Cutaneous Lupus Erythematosus Subtypes: A Prospective Observational Study in Asians. Chanprapaph K; Tankunakorn J; Suchonwanit P; Rutnin S Dermatol Ther (Heidelb); 2021 Feb; 11(1):131-147. PubMed ID: 33280074 [TBL] [Abstract][Full Text] [Related]
20. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients. Chanprapaph K; Tubtieng I; Pratumchat N; Thadanipon K; Rattanakaemakorn P; Suchonwanit P Lupus; 2021 Apr; 30(5):785-794. PubMed ID: 33554715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]